A proposed microbiome therapeutic against CRE and VRE, comprising a synthetic microbial consortium and inhibitory metabolites.

A proposed microbiome therapeutic against CRE and VRE, comprising a synthetic microbial consortium and inhibitory metabolites.
Dr Britany Clarke is an Industry Partnership and Commercialisation Officer in the Faculty of Medicine at Imperial College London.
A microfluidic device designed to accelerate the development of T-cell immunotherapies for cancer.
Diana supports and leads on the commercialisation of MedTech, and HealthTech related technologies from Imperial’s Faculty of Engineering
A method for fine-tuning gene expression in Yarrowia Lipoltica
A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics
A novel approach to light-sheet fluorescence microscopy that uses a folded optical configuration to achieve both sample scanning and dual-view image acquisition.
Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property;...
A novel gene therapy for Huntington’s Disease that leverage zinc finger protein technology.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.